oxiracetam oxiracetam oxiracetam (developmental code name isf 2522) is a nootropic drug of the racetam family and a very mild stimulant. several studies suggest that the substance is safe even when high doses are consumed for a long period of time. however, the mechanism of action of the racetam drug family is still a matter of research. oxiracetam is not approved by food and drug administration for any medical use in the united states. oxiracetamclinical dataroutes ofadministrationoralatc coden06bx07 (who) legal statuslegal status au: s4 (prescription only) us: unscheduled pharmacokinetic databioavailability56-82%onset of action30-90 minuteselimination half-life8 hoursexcretionrenalidentifiers iupac name (rs)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide cas number62613-82-5 npubchem cid4626chemspider4465 yuniip7u817352gkeggd07346 ychemblchembl36633 ycomptox dashboard (epa)dtxsid9045180 echa infocard100.164.173 chemical and physical dataformulac6h10n2o3molar mass158.155 g·mol−13d model (jsmol)interactive imagechiralityracemic mixture smiles o=c(n)cn1c(=o)cc(o)c1 inchi inchi=1s/c6h10n2o3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9h,1-3h2,(h2,7,10) ykey:ihlaqqpqkrmgss-uhfffaoysa-n y ny (what is this?) (verify) clinical findings there has been effort put into investigating the possible use of oxiracetam as a medication to attenuate the symptoms of dementia. however, no convincing results were obtained from studies of patients with alzheimer's dementia or organic solvent abuse. tests performed on patients with mild to moderate dementia experienced beneficial effects measured by higher scores on tests for logical performance, attention, concentration, memory and spatial orientation. improvement was also seen in patients with exogenic post-concussion syndrome, organic brain syndromes and other dementias. oxiracetam-treated dba mice demonstrated a significant increase in spatial learning performance as determined by the morris water navigation task, compared to controls. this increase in performance was correlated to an increase in membrane-bound pkc. pharmacokinetics oxiracetam is well absorbed from the gastrointestinal tract with a bioavailability of 56-82%. peak serum levels are reached within one to three hours after a single 800 mg or 2000 mg oral dose, with the maximal serum concentration reaching between 19 and 31 μg/ml at these doses. oxiracetam is mainly cleared renally and approximately 84% is excreted unchanged in the urine. the half-life of oxiracetam in healthy individuals is about 8 hours, whereas it is 10–68 hours in patients with renal impairment. there is some penetration of the blood–brain barrier with brain concentrations reaching 5.3% of those in the blood (measured one hour after a single 2000 mg intravenous dose). clearance rates range from 9 to 95 ml/min and steady-state concentrations when 800 mg is given twice daily range from 60 μm to 530 μm. the highest brain concentrations of oxiracetam are found in the septum pellucidum, followed by the hippocampus, the cerebral cortex and with the lowest concentrations in the striatum after a 200 mg/kg oral dose given to rats. oxiracetam may be quantitated in plasma, serum or urine by liquid chromatography with one of several different detection techniques. the major metabolites of oxiracetam include: beta-hydroxy-2-pyrrolidone, n-aminoacetyl-gabob, gabob (beta-hydroxy-gaba) and glycine. thus its metabolic route is exactly parallel to that of piracetam, aniracetam, phenylpiracetam, and all other members of the -racetam family, and also pyroglutamic acid.